The University of Chicago Header Logo

Connection

Everett Vokes to Carcinoma, Non-Small-Cell Lung

Back to Details
This is a "connection" page, showing publications Everett Vokes has written about Carcinoma, Non-Small-Cell Lung.
Everett Vokes
Connection Strength
12.357
Carcinoma, Non-Small-Cell Lung
  1. Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study. J Thorac Oncol. 2024 02; 19(2):285-296.
    View in: PubMed
    Score: 0.417
  2. Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal. J Clin Oncol. 2023 09 01; 41(25):4093-4096.
    View in: PubMed
    Score: 0.409
  3. Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. N Engl J Med. 2023 02 09; 388(6):489-498.
    View in: PubMed
    Score: 0.399
  4. Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2021 09; 159:56-65.
    View in: PubMed
    Score: 0.358
  5. Beyond PACIFIC: Uncharted Waters. J Thorac Oncol. 2021 05; 16(5):715-718.
    View in: PubMed
    Score: 0.353
  6. The Impact of Staging by Positron-Emission Tomography on Overall Survival and Progression-Free Survival in Patients With Locally Advanced NSCLC. J Thorac Oncol. 2018 08; 13(8):1183-1188.
    View in: PubMed
    Score: 0.287
  7. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018 04 01; 29(4):959-965.
    View in: PubMed
    Score: 0.285
  8. Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). Int J Radiat Oncol Biol Phys. 2018 05 01; 101(1):177-185.
    View in: PubMed
    Score: 0.282
  9. ALK and ROS1 rearrangement in NSCLC: rapidly evolving standards. Lancet Oncol. 2017 12; 18(12):1555-1556.
    View in: PubMed
    Score: 0.276
  10. Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance). J Thorac Oncol. 2017 05; 12(5):843-849.
    View in: PubMed
    Score: 0.263
  11. Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. J Clin Oncol. 2016 11 20; 34(33):3992-3999.
    View in: PubMed
    Score: 0.257
  12. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer. 2014 Jan 04; 14:5.
    View in: PubMed
    Score: 0.212
  13. New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. J Clin Oncol. 2013 Mar 10; 31(8):1029-38.
    View in: PubMed
    Score: 0.199
  14. Non-small-cell lung cancer: then and now. J Clin Oncol. 2013 Mar 10; 31(8):981-3.
    View in: PubMed
    Score: 0.199
  15. Evidence-based role of bevacizumab in non-small cell lung cancer. Ann Oncol. 2013 Jan; 24(1):6-9.
    View in: PubMed
    Score: 0.198
  16. Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer. J Clin Oncol. 2012 Jun 01; 30(16):2019-20; author reply 2020.
    View in: PubMed
    Score: 0.188
  17. Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer. Oncol Rep. 2012 May; 27(5):1625-9.
    View in: PubMed
    Score: 0.186
  18. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer. 2012 Mar; 13(2):123-8.
    View in: PubMed
    Score: 0.183
  19. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol. 2011 Aug 10; 29(23):3120-5.
    View in: PubMed
    Score: 0.179
  20. The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist. 2009 Nov; 14(11):1116-30.
    View in: PubMed
    Score: 0.159
  21. Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. J Clin Oncol. 2009 Sep 20; 27(27):4487-91.
    View in: PubMed
    Score: 0.157
  22. PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer. 2009 May; 10(3):193-8.
    View in: PubMed
    Score: 0.153
  23. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
    View in: PubMed
    Score: 0.147
  24. Locally advanced non-small cell lung cancer: the past, present, and future. J Thorac Oncol. 2008 Aug; 3(8):917-28.
    View in: PubMed
    Score: 0.146
  25. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol. 2008 May 20; 26(15):2457-63.
    View in: PubMed
    Score: 0.144
  26. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007 May 01; 25(13):1698-704.
    View in: PubMed
    Score: 0.133
  27. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):515-22.
    View in: PubMed
    Score: 0.131
  28. Angiogenesis inhibition in the treatment of lung cancer. Clin Adv Hematol Oncol. 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2.
    View in: PubMed
    Score: 0.129
  29. Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA. 2026 Aug 11; 336(6):464-472.
    View in: PubMed
    Score: 0.127
  30. The cancer and leukemia group B respiratory committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3581s-8s.
    View in: PubMed
    Score: 0.125
  31. Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. J Thorac Oncol. 2006 Mar; 1(3):245-51.
    View in: PubMed
    Score: 0.123
  32. Adjuvant and neoadjuvant therapy for early-stage non-small-cell lung cancer. Clin Lung Cancer. 2005 Dec; 7 Suppl 3:S98-104.
    View in: PubMed
    Score: 0.121
  33. Seeking improved outcome in the curative treatment of non-small-cell lung cancer. Lung Cancer. 2005 Oct; 50 Suppl 1:S20-2.
    View in: PubMed
    Score: 0.120
  34. Optimal therapy for unresectable stage III non-small-cell lung cancer. J Clin Oncol. 2005 Sep 01; 23(25):5853-5.
    View in: PubMed
    Score: 0.119
  35. Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):5045s-5050s.
    View in: PubMed
    Score: 0.118
  36. Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial. JAMA Oncol. 2024 09 01; 10(9):1212-1219.
    View in: PubMed
    Score: 0.111
  37. Recurrence of Non-Small Cell Lung Cancer With Visceral Pleural Invasion: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2024 09 01; 10(9):1179-1186.
    View in: PubMed
    Score: 0.111
  38. Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC. J Thorac Oncol. 2024 07; 19(7):1108-1116.
    View in: PubMed
    Score: 0.107
  39. Induction chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. Hematol Oncol Clin North Am. 2004 Feb; 18(1):81-90.
    View in: PubMed
    Score: 0.107
  40. Induction or consolidation systemic therapy in the multimodality treatment of unresectable locally advanced non-small cell lung cancer. Lung Cancer. 2003 Dec; 42 Suppl 1:S65-9.
    View in: PubMed
    Score: 0.105
  41. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial. J Thorac Oncol. 2023 12; 18(12):1731-1742.
    View in: PubMed
    Score: 0.103
  42. Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting. Lung Cancer. 2003 Aug; 41 Suppl 1:S115-21.
    View in: PubMed
    Score: 0.103
  43. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003 May 01; 21(9):1760-6.
    View in: PubMed
    Score: 0.101
  44. Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer. Future Oncol. 2023 Mar; 19(8):549-557.
    View in: PubMed
    Score: 0.100
  45. A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer. 2003 Feb; 39(2):191-6.
    View in: PubMed
    Score: 0.100
  46. STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2023 01; 7:e2200273.
    View in: PubMed
    Score: 0.099
  47. Adjuvant and neoadjuvant treatments for NSCLC. Lung Cancer. 2002 Dec; 38 Suppl 4:29-35.
    View in: PubMed
    Score: 0.098
  48. Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer. 2022 12; 3(12):1498-1512.
    View in: PubMed
    Score: 0.098
  49. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 02 10; 41(5):1105-1115.
    View in: PubMed
    Score: 0.098
  50. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol. 2002 Oct 15; 20(20):4191-8.
    View in: PubMed
    Score: 0.098
  51. Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. Lung Cancer. 2002 Oct; 38(1):65-71.
    View in: PubMed
    Score: 0.097
  52. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022 05 26; 386(21):1973-1985.
    View in: PubMed
    Score: 0.094
  53. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
    View in: PubMed
    Score: 0.091
  54. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140.
    View in: PubMed
    Score: 0.090
  55. Trends and perspectives in multimodality therapy of locoregionally advanced non-small cell lung cancer. Lung Cancer. 2001 Sep; 33 Suppl 1:S85-9.
    View in: PubMed
    Score: 0.090
  56. Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study. J Clin Oncol. 2021 11 10; 39(32):3633-3644.
    View in: PubMed
    Score: 0.090
  57. Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. Clin Cancer Res. 2021 11 01; 27(21):5781-5792.
    View in: PubMed
    Score: 0.090
  58. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 03 01; 39(7):723-733.
    View in: PubMed
    Score: 0.086
  59. Induction chemotherapy followed by concomitant chemoradiotherapy for non-small cell lung cancer. Oncologist. 2001; 6 Suppl 1:25-7.
    View in: PubMed
    Score: 0.086
  60. A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer. Invest New Drugs. 2001; 19(4):329-33.
    View in: PubMed
    Score: 0.086
  61. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. Lancet Oncol. 2020 12; 21(12):1589-1601.
    View in: PubMed
    Score: 0.085
  62. Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay. J Thorac Oncol. 2020 08; 15(8):1306-1316.
    View in: PubMed
    Score: 0.082
  63. Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer. Curr Med Res Opin. 2019 10; 35(10):1761-1767.
    View in: PubMed
    Score: 0.078
  64. Clinical prognostic model for older patients with advanced non-small cell lung cancer. J Geriatr Oncol. 2019 07; 10(4):555-559.
    View in: PubMed
    Score: 0.076
  65. Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). Lancet Respir Med. 2018 12; 6(12):915-924.
    View in: PubMed
    Score: 0.074
  66. Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 02; 14(2):298-303.
    View in: PubMed
    Score: 0.074
  67. Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC. J Thorac Oncol. 2018 08; 13(8):1171-1182.
    View in: PubMed
    Score: 0.071
  68. Feasibility of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Cytology Specimens for Next Generation Sequencing in Non-small-cell Lung Cancer. Clin Lung Cancer. 2018 05; 19(3):230-238.e2.
    View in: PubMed
    Score: 0.070
  69. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017 Dec 10; 35(35):3924-3933.
    View in: PubMed
    Score: 0.069
  70. Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. Sci Rep. 2017 08 23; 7(1):9192.
    View in: PubMed
    Score: 0.068
  71. Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. J Clin Oncol. 2017 Sep 01; 35(25):2885-2892.
    View in: PubMed
    Score: 0.067
  72. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. J Thorac Oncol. 2017 02; 12(2):194-207.
    View in: PubMed
    Score: 0.064
  73. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget. 2016 Apr 05; 7(14):18876-86.
    View in: PubMed
    Score: 0.062
  74. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Mar 20; 34(9):953-62.
    View in: PubMed
    Score: 0.061
  75. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. Clin Cancer Res. 2015 Dec 15; 21(24):5439-44.
    View in: PubMed
    Score: 0.061
  76. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Oct 22; 373(17):1627-39.
    View in: PubMed
    Score: 0.060
  77. Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups. Lung Cancer. 2015 Nov; 90(2):281-7.
    View in: PubMed
    Score: 0.059
  78. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 09; 373(2):123-35.
    View in: PubMed
    Score: 0.058
  79. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res. 2015 Apr 01; 21(7):1514-24.
    View in: PubMed
    Score: 0.057
  80. A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol. 2015 Jan; 10(1):143-7.
    View in: PubMed
    Score: 0.057
  81. Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer. BMC Cancer. 2014 Mar 14; 14:185.
    View in: PubMed
    Score: 0.054
  82. CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol. 2014 Feb; 9(2):214-21.
    View in: PubMed
    Score: 0.053
  83. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer Res. 2014 Feb 01; 74(3):884-95.
    View in: PubMed
    Score: 0.053
  84. Differential expression of RON in small and non-small cell lung cancers. Genes Chromosomes Cancer. 2012 Sep; 51(9):841-51.
    View in: PubMed
    Score: 0.047
  85. CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. J Thorac Oncol. 2012 Apr; 7(4):649-54.
    View in: PubMed
    Score: 0.047
  86. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol. 2012 Mar; 7(3):574-8.
    View in: PubMed
    Score: 0.047
  87. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):376-81.
    View in: PubMed
    Score: 0.046
  88. Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304. J Thorac Oncol. 2011 Nov; 6(11):1902-6.
    View in: PubMed
    Score: 0.046
  89. A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531. Lung Cancer. 2011 Nov; 74(2):258-63.
    View in: PubMed
    Score: 0.044
  90. Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e269-74.
    View in: PubMed
    Score: 0.044
  91. MET and phosphorylated MET as potential biomarkers in lung cancer. J Environ Pathol Toxicol Oncol. 2011; 30(4):341-54.
    View in: PubMed
    Score: 0.043
  92. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol. 2010 Sep; 5(9):1382-90.
    View in: PubMed
    Score: 0.042
  93. Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. J Thorac Oncol. 2010 Jun; 5(6):810-7.
    View in: PubMed
    Score: 0.041
  94. Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. J Clin Oncol. 2010 Jan 10; 28(2):202-6.
    View in: PubMed
    Score: 0.040
  95. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol. 2010 Jan 01; 28(1):56-62.
    View in: PubMed
    Score: 0.040
  96. Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2009 Sep; 4(9):1117-25.
    View in: PubMed
    Score: 0.039
  97. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol. 2009 Aug 10; 27(23):3836-41.
    View in: PubMed
    Score: 0.039
  98. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer. 2009 Apr 15; 115(8):1713-22.
    View in: PubMed
    Score: 0.038
  99. Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430. J Thorac Oncol. 2008 Nov; 3(11):1301-7.
    View in: PubMed
    Score: 0.037
  100. Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer. Clin Lung Cancer. 2008 Nov; 9(6):346-51.
    View in: PubMed
    Score: 0.037
  101. Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). J Thorac Oncol. 2008 Oct; 3(10):1159-65.
    View in: PubMed
    Score: 0.037
  102. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008 Nov 01; 26(31):5043-51.
    View in: PubMed
    Score: 0.037
  103. Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress? Clin Lung Cancer. 2008 Mar; 9(2):85-91.
    View in: PubMed
    Score: 0.035
  104. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. J Clin Oncol. 2008 Feb 20; 26(6):848-55.
    View in: PubMed
    Score: 0.035
  105. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer. J Thorac Oncol. 2008 Jan; 3(1):59-67.
    View in: PubMed
    Score: 0.035
  106. Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer. Clin Lung Cancer. 2008 Jan; 9(1):9-15.
    View in: PubMed
    Score: 0.035
  107. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial. J Thorac Oncol. 2007 Oct; 2(10):933-8.
    View in: PubMed
    Score: 0.034
  108. A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734. Clin Lung Cancer. 2007 Jan; 8(4):268-72.
    View in: PubMed
    Score: 0.033
  109. Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):4981s-4983s.
    View in: PubMed
    Score: 0.029
  110. Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534. Clin Lung Cancer. 2005 Jul; 7(1):47-53.
    View in: PubMed
    Score: 0.029
  111. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol. 2004 Dec; 25(6):1677-83.
    View in: PubMed
    Score: 0.028
  112. Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress. Clin Lung Cancer. 2009 Nov; 10(6):395-404.
    View in: PubMed
    Score: 0.010
  113. MET as a target for treatment of chest tumors. Lung Cancer. 2009 Feb; 63(2):169-79.
    View in: PubMed
    Score: 0.009
  114. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 01; 26(7):1119-27.
    View in: PubMed
    Score: 0.009
  115. Irinogenetics: what is the right star? J Clin Oncol. 2006 May 20; 24(15):2221-4.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.